Modeling Parkinson's disease in monkeys for translational studies, a critical analysis

Experimental Neurology

Volumn 256, Issue , 2014, Pages 133-143

  Potts, Lisa F ^a   Wu, Hao ^b   Singh, Arun ^a   Marcilla, Irene ^c   Luquin, Maria R ^c   Papa, Stella M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Dyskinesia; Model; MPTP; Non human primate; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEVODOPA;

CATECHOLAMINE DEPLETION; DYSKINESIA; MACACA FASCICULARIS; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHENOTYPE; PRIMATE MODEL; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SAMPLE SIZE; SENSITIVITY ANALYSIS; TRANSLATIONAL RESEARCH;

DYSKINESIA; MODEL; MPTP; NON-HUMAN PRIMATE; PARKINSON'S DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; MACACA; MPTP POISONING; PARKINSON DISEASE, SECONDARY;

EID: 84900826387     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.09.014     Document Type: Review

References (58)

1. Algeri S., Ambrosio S., Garofalo P., Gerli P. Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. Eur. J. Pharmacol. 1987, 141:309-312.
2. Ambrosio S., Blesa R., Mintenig G.M., Palacios-Araus L., Mahy N., Gual A. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat. Toxicol. Lett. 1988, 44:1-6.
3. Armentero M.T., Pinna A., Ferre S., Lanciego J.L., Muller C.E., Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 2011, 132(3):280-299.
4. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 1986, 39:7-16.
5. Barraud Q., Lambrecq V., Forni C., McGuire S., Hill M., Bioulac B., Balzamo E., Bezard E., Tison F., Ghorayeb I. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp. Neurol. 2009, 219:574-582.
6. Bezard E., Przedborski S. A tale on animal models of Parkinson's disease. Mov. Disord. 2011, 26:993-1002.
7. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
8. Bibbiani F., Costantini L.C., Patel R., Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 2005, 192:73-78.
9. Bloem B.R., Irwin I., Buruma O.J., Haan J., Roos R.A., Tetrud J.W., Langston J.W. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J. Neurol. Sci. 1990, 97:273-293.
10. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:4546-4550.
11. Capitanio J.P., Emborg M.E. Contributions of non-human primates to neuroscience research. Lancet 2008, 371:1126-1135.
12. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
13. Chaumette T., Derkinderen P., Bruley des Varannes S., Bezard E., Accary D., Li Q., Qin C., Lardeux B., Aubert P., Lebouvier T., Neunlist M. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 2009, 21:215-222.
14. Collier T.J., Steece-Collier K., Kordower J.H. Primate models of Parkinson's disease. Exp. Neurol. 2003, 183:258-262.
15. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
16. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164(4):1357-1391.
17. Eden R.J., Costall B., Domeney A.M., Gerrard P.A., Harvey C.A., Kelly M.E., Naylor R.J., Owen D.A., Wright A. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 1991, 38:147-154.
18. Eidelberg E., Brooks B.A., Morgan W.W., Walden J.G., Kokemoor R.H. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 1986, 18:817-822.
19. Elsworth J.D., Taylor J.R., Sladek J.R., Collier T.J., Redmond D.E., Roth R.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 2000, 95:399-408.
20. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J. 2007, 48:339-355.
21. Fernandez H.H., Greeley D.R., Zweig R.M., Wojcieszek J., Mori A., Sussman N.M. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat. Disord. 2010, 16:16-20.
22. Fornai F., Vaglini F., Maggio R., Bonuccelli U., Corsini G.U. Species differences in the role of excitatory amino acids in experimental parkinsonism. Neurosci. Biobehav. Rev. 1997, 21:401-415.
23. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 1986, 20:449-455.
24. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv. Neurol. 1993, 60:600-608.
25. Fox S.H., Brotchie J.M. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 2010, 184:133-157.
26. Gibb W.R., Terruli M., Lees A.J., Jenner P., Marsden C.D. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov. Disord. 1989, 4:53-74.
27. Hadj Tahar A., Ekesbo A., Gregoire L., Bangassoro E., Svensson K.A., Tedroff J., Bedard P.J. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur. J. Pharmacol. 2001, 412:247-254.
28. Iravani M.M., Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J. Neural Transm. 2011, 118:1661-1690.
29. Jakowec M.W., Petzinger G.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. 2004, 54:497-513.
30. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 2000, 47:S90-S104.
31. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003, 61:S4-S11.
32. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677.
33. Johannessen J.N., Chiueh C.C., Burns R.S., Markey S.P. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 1985, 36:219-224.
34. Johnston T.H., Fox S.H., McIldowie M.J., Piggott M.J., Brotchie J.M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2010, 333:865-873.
35. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
36. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
37. Liang L., DeLong M.R., Papa S.M. Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements. J. Neurosci. 2008, 28:7537-7547.
38. Luquin M.R., Laguna J., Obeso J.A. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann. Neurol. 1992, 31:551-554.
39. Luquin M.R., Montoro R.J., Guillen J., Saldise L., Insausti R., Del Rio J., Lopez-Barneo J. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 1999, 22:743-750.
40. Marin C., Rodriguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 2006, 197:269-274.
41. Morin N., Jourdain V.A., Di Paolo T. Modeling dyskinesia in animal models of Parkinson disease. Exp. Neurol. 2013, 256:105-116.
42. Mounayar S., Boulet S., Tande D., Jan C., Pessiglione M., Hirsch E.C., Feger J., Savasta M., Francois C., Tremblay L. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 2007, 130:2898-2914.
43. Olanow C.W., Kordower J.H. Modeling Parkinson's disease. Ann. Neurol. 2009, 66:432-436.
44. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., Deglon N., Hantraye P., Aebischer P., Kordower J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 2002, 22:4942-4954.
45. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 1996, 39:574-578.
46. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994, 662:69-74.
47. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 2001, 76:1265-1274.
48. R, D.C.T. R: A Language and Environment for Statistical Computing 2011, R Foundation for Statistical Computing, Vienna, Austria.
49. Samadi P., Gregoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L.T., Bedard P.J., Di Paolo T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 2008, 29:1040-1051.
50. Schneider J.S., Roeltgen D.P. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res. 1993, 615:351-354.
51. Schneider J.S., Tinker J.P., Van Velson M., Menzaghi F., Lloyd G.K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 1999, 290:731-739.
52. Schneider J.S., Tinker J.P., Decamp E. Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism. Behav. Brain Res. 2010, 211:236-239.
53. Song D.D., Haber S.N. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J. Neurosci. 2000, 20:5102-5114.
54. Stockwell K.A., Scheller D., Rose S., Jackson M.J., Tayarani-Binazir K., Iravani M.M., Smith L.A., Olanow C.W., Jenner P. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp. Neurol. 2009, 219:533-542.
55. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Redmond D.E. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81:745-755.
56. Vazquez-Claverie M., Garrido-Gil P., San Sebastian W., Izal-Azcarate A., Belzunegui S., Marcilla I., Lopez B., Luquin M.R. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J. Neuropathol. Exp. Neurol. 2009, 68:977-984.
57. Waters C.M., Hunt S.P., Jenner P., Marsden C.D. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience 1987, 23:1025-1039.
58. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.